TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07034690: A Prospective, Type I Hybrid Effectiveness-implementation, Open Label, Randomized Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in at- Risk Adult Patients From Abu Dhabi, United A

Sponsor: Novartis Pharmaceuticals · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 326 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,499,200

Rescue Site Savings

+$5,604,160

Unlock Full NCT07034690 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07034690 Rescue Dossier →